At Selecta Biosciences, we are developing an entirely new class of targeted immunotherapies and vaccines that induces an antigen-specific immune activation or an antigen-specific immune tolerance for therapeutic and prophylactic applications.
Our proprietary technology platform is based on innovations in nanotechnology and immunology discovered at MIT and Harvard Medical School. Selecta's platform is designed to create robust immune responses to a wide range of antigens while limiting adverse events.
We are focusing on building a pipeline with a broad range of product candidates in infectious diseases, respiratory, oncology, autoimmunity, and allergies. Our initial product candidate is a first-in-class synthetic vaccine against nicotine for the critically underserved worldwide market of smoking cessation and relapse prevention.